Christopher Peetz - 23 Jan 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Jan 2025, 16:48:06 UTC
Prior SEC filing
23 Jan 2025
Next SEC filing
04 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Christopher Peetz filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 27 Jan 2025.

Key facts

  • This page summarizes Christopher Peetz's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 27 Jan 2025, 16:48.

Change

  • Previous filing in this sequence was filed on 23 Jan 2025.
  • Current net transaction value: -$327,658.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,500
Change %
+10%
Price
Shares after
131,859
Date
23 Jan 2025
Ownership
Direct
Footnotes
F1
MIRM transaction

Common Stock

Sale

Transaction value
$327,658
Shares
-6,837
Change %
-5.2%
Price
$47.92
Shares after
125,022
Date
24 Jan 2025
Ownership
Direct
Footnotes
F2
MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
208,570
Date
23 Jan 2025
Ownership
By The Peetz Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-12,500
Change %
-33%
Price
$0.000000
Shares after
25,000
Date
23 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,500
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Footnote F3

1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .